Potential Chemoprotectants Platinum- Based Therapy with S-ligand Using ATP Bioluminescence Assay
DOI:
https://doi.org/10.61841/fzjx1r04Keywords:
chemoprotectants, S-based ligand, Mesna, ATP bioluminescence assayAbstract
The critical dose limiting side effect of cisplatin is nephrotoxicity; 20% of patients receiving a high dose of cisplatin have suffered from severe renal dysfunction; the ability to manage this induced toxicity is crucial for the success of chemotherapy. The concomitant administration of chemoprotective agents become an important approach in a platinum chemotherapy, the potential reversibility of Pt-S bonds in presence of other sulfur ligands suggests that certain Pt-bound sulfur ligand can be substituted by other sulfur nucleophiles, and Pt can be transferred between various S-containing molecules which form the chemical basis to alleviate the acute platinum toxicity using chemoprotectants. This research concerned with the cytotoxicity studies of already prepared new Pt(II) complexes with S-donor ligands, mesna and dimesna; using ATP bioluminescence assay against HeLa, BEAS-2B and A549. The best results were obtained with A549 cell line and were not differing significalnty from the contol (cisplatin), Our fininding sugggest that there are potenitainls in delivering the chemoprotection with acceptable cytotoxicity.
Downloads
References
1. Abhishek Basu, Arin Bhattacharjee, & Sudin Bhattacharya. (2016). Chemoprotectants in Cancer Chemotherapy: An Update. Biomed Res J, 3(2), 157–181.
2. Bugarcic, Z. D., Bogojeski, J., Petrovic, B., et al. (2012). Mechanistic studies on the reactions of platinum (II) complexes with nitrogen- and sulfur-donor biomolecules. Dalton Transactions, 41(40), 12313–12363. https://doi.org/10.1039/c2dt31045g
3. Cao, X., Nie, X., Xiong, S., Cao, L., Wu, Z., Moore, P. K., & Bian, J. S. (2018). Renal protective effect of polysulfide in cisplatin-induced nephrotoxicity. Redox Biology, 15, 513–521.
4. Crump, D., Chiu, S., & Kennedy, S. W. (2012). Effects of Tris(1,3-dichloro-2-propyl) phosphate and Tris(1-chloropropyl) phosphate on cytotoxicity and mRNA expression in primary cultures of avian hepatocytes and neuronal cells. Toxicological Sciences, 126(1), 140–148.
5. Cutler, M. J. (2010). Pharmacokinetics and Therapeutic Uses of Mesna (M.Sc. Thesis). University of Western Ontario, Canada.
6. Datt, M. S. (2001). Synthesis and Characterization of Novel Platinum(II) Complexes: Potential Chemotherapeutic Drugs (Ph.D. Thesis). Rhodes University, Grahamstown, South Africa.
7. Dawson, T. P., Ashton, K., Golash, A., Charles H. G., & Davis, Ch. H. (2011). Cell survival assay for individualized chemotherapy in primary glioma cultures—colorimetric or luminescent? Neuroscience and Medicine, 2, 376–383. https://doi.org/10.4236/nm.2011.24050
8. Duffy, E. A., Fitzgerald, W., Boyle, K., & Rohatgi, R. (2018). Nephrotoxicity: Evidence in patients receiving cisplatin therapy. Clinical Journal of Oncology Nursing, 22(2), 175–183.
9. Farrell, N. (1982). Dimethyl sulfoxide as leaving group: applications in transition metal chemotherapy. Journal of Chemical Society, Chemical Communication, 6, 331–332.
10. Hannon, M. J. (2007). Metal-based anticancer drugs: From a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biology. Pure and Applied Chemistry, 79(12), 2243–2261. https://doi.org/10.1351/pac200779122243
11. Hausheer, F. H., Ding, D., Shanmugarajah, D., Leverett, B. D., Huang, Q., Chen, X., Kochat, H., Ayala, P. Y., Petluru, P. N., & Parker, A. R. (2011). Accumulation of BNP7787 in human renal proximal tubule cells. Journal of Pharmacological Sciences, 100(9), 3977–3984. https://doi.org/10.1002/jps.22510
12. Hausheer F. H., Ding D., Shanmugarajah D., et al. (2011). Accumulation of BNP7787 in human renal proximal tubule cells. Journal of Pharmacological Sciences, 100(9), 3977–3984. https://doi.org/10.1002/jps.22510
13. He, B., Liu, X., Yue, W., & Zhou, A. (2009). Rapid detection of bacteria without cultivation with a portable bioluminescence sensor system. African Journal of Microbiology Research, 3(9), 575–580. http://lifesciences.tecan.com
14. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018057s083lbl.pdf (accessed 15.10.18).
15. Kangarloo, S. B., Gangopadhyay, S. B., Syme, R. M., Johannes, E. A., Wolff, S. G. Influence of Mesna on the Pharmacokinetics of Cisplatin and Carboplatin in Pediatric Cancer Patients. Medical Oncology, 21(1), 9–19. https://doi.org/10.1385/MO:21:1:09
16. Kintzel, P. E. (2006). Guideline for Cytoprotectant Agents. Pharmacy Practice News, Educational Review (19–23).
17. Kreahling, J. M., & Altiok, S. (2015). Special technologies for ex vivo analysis of cancer. Cancer Control, 22(2), 226–231.
18. Lippert, B. (1999). Cisplatin Chemistry and Biochemistry of a Leading Anticancer Drug. Wiley-VCH, Germany & VHCA, Switzerland. pp. 339–359.
19. Marija Petrovic, & Danijela Todorovic. (2016). Biochemical and molecular mechanisms of action of cisplatin in cancer cells. Med. Biol., 18(1), 12–18.
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
